Preclinical data using an anti-CD138 CAR, generated after transduction of the NK‐92MI cell line (which express human IL-2) (185), with the CD138-CD3ζ vector, showed enhanced cytotoxicity on CD138+ MM cells in vitro and in vivo (186). The gene discussed is SDC1; the disease is Miyoshi myopathy.